Literature DB >> 9856408

Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma.

V Toscano1.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9856408     DOI： 10.1007/BF03350779

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  44 in total

Review 1.  The ubiquitous polycystic ovary.

Authors:  S Franks
Journal:  J Endocrinol       Date:  1991-06       Impact factor: 4.286

Review 2.  Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

3.  Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome.

Authors:  D M Waterworth; S T Bennett; N Gharani; M I McCarthy; S Hague; S Batty; G S Conway; D White; J A Todd; S Franks; R Williamson
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

Review 4.  Hyperandrogenicity in women--a prediabetic condition?

Authors:  P Björntorp
Journal:  J Intern Med       Date:  1993-12       Impact factor: 8.989

Review 5.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 6.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

7.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

8.  Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

Authors:  E M Velazquez; S Mendoza; T Hamer; F Sosa; C J Glueck
Journal:  Metabolism       Date:  1994-05       Impact factor: 8.694

9.  Effects of dihydrotestosterone treatment on adrenal gland function and morphology in adult female guinea-pigs.

Authors:  V Toscano; S Caiola; M Maroder; M V Adamo; L Argiolas; A Familiari; G Familiari
Journal:  J Steroid Biochem       Date:  1990-06       Impact factor: 4.292

10.  Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth.

Authors:  L Ibáñez; N Potau; I Francois; F de Zegher
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958
View more
  2 in total

1.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

2.  Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism?

Authors:  F Orio; S Palomba; T Cascella; L Tauchmanovà; S Di Biase; D Labella; T Russo; M Pellicano; S Savastano; F Zullo; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.